Journal article
The economics of adalimumab for ulcerative colitis
Abstract
Ulcerative colitis is a chronic inflammatory disease, characterized by diffuse mucosal inflammation in the colon. Adalimumab, as a TNF-α blocker, offers a safe and efficacious treatment option for patients with moderate to severe ulcerative colitis and refractory or intolerant to conventional medications; however, its cost-effectiveness profile has not yet been well established. Future economic evaluations should choose appropriate comparators …
Authors
Xie F
Journal
Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 15, No. 3, pp. 373–377
Publisher
Taylor & Francis
Publication Date
May 4, 2015
DOI
10.1586/14737167.2015.1031113
ISSN
1473-7167